Key takeaway: Shaily Engineering Plastics Limited provided an investor presentation detailing its Q1 FY27 performance. The presentation highlighted a 14% increase in revenues, reaching Rs. 280.7 crore, compared to Rs. 246.7 crore in Q1 FY26. Key financial metrics included an 18% rise in EBITDA to Rs. 83.3 crore and a 17% increase in profit after tax to Rs. 48.0 crore. The healthcare segment showed significant growth, with an 85% increase in revenue, while the consumer segment experienced a 24% decline. Management reported new project confirmations from various sectors, including FMCG, automotive, and healthcare. The company emphasized improved operational efficiency, with a rise in machine utilization and return on capital employed. The presentation also noted a stable credit rating of CARE A+ and highlighted the company's long-standing relationships with clients across diverse industries. The document stated that the earnings call was scheduled for August 10, 2026, to discuss these results further.

Key takeaway: The earnings call for Shaily Engineering Plastics Limited on May 20, 2026, highlighted the company's operational and financial performance for Q4 and FY '26. Management noted heightened geopolitical uncertainty affecting supply chains and input costs but reported stable navigation through these challenges. A significant milestone was achieved with the commercial launch of Shaily Harmony and Shaily Neo pen injectors for Semaglutide, marking entry into regulated markets like Canada and tentative approval in the U.S. The healthcare segment saw a revenue surge of 139% year-on-year, while the consumer segment experienced a 9% decline due to weaker demand in key markets. The industrial segment grew by 41%. Management announced a resolution to raise up to INR500 crores to maintain financial flexibility for future opportunities. The call concluded with a focus on scaling operations and maintaining growth across various segments.

Key takeaway: During the Q3 FY '26 earnings call, management reported a strong revenue growth of 27% year-on-year, reaching INR 251 crores, with EBITDA increasing by 43% to INR 66 crores. The healthcare segment's contribution to revenue doubled to 42%, driven by new contracts and the establishment of a new facility in Abu Dhabi for pen and auto-injectors, with an investment of AED 130 million to AED 150 million. Management announced the appointment of a new Chief Operating Officer for the healthcare division and highlighted ongoing discussions with the Abu Dhabi government for potential financial support. The consumer segment saw a revenue decline of 13%, attributed to a slowdown in demand in Europe and the U.S. Management noted that the company is focused on expanding its capacity and improving operational efficiency, with plans for new lines to be operational by mid-2026. The call concluded with management expressing confidence in future growth despite current challenges in the consumer segment.

Key takeaway: The investor presentation from Shaily Engineering Plastics Limited, dated February 12, 2026, outlines the company's operational and financial performance for Q3 FY26 and the nine months ending December 31, 2025. Management reported a 27% increase in revenues year-over-year for Q3, reaching Rs. 250.5 crore, with a notable improvement in gross profit margins. The company highlighted the appointment of a new COO for Healthcare, Mr. Joe Kam, effective March 1, 2026, to enhance operational excellence. Additionally, Shaily announced plans to establish a new manufacturing facility in Abu Dhabi, with an investment of AED 130-150 million aimed at expanding its global footprint. The presentation also detailed significant growth in the healthcare segment, contributing to overall business growth. Financial metrics showed substantial increases in profit after tax and EBITDA margins compared to the previous year.